González-Ramírez MP, Miravete-Lagunes K, Gómez-de-León A, Poncede-León S, Tenorio-Rojo AP, Martagón-Herrera NA, Hernández-Reyes JA, García-Villasenor A, Burguette E, Vallejo-Villalobos MF, Ruiz-Delgado GJ, Gómez-Almaguer D, Ruiz-Argüelles GJ

Idioma: Ingles.
Referencias bibliográficas: 17
Paginas: 109-116
Archivo PDF: 185.08 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Pîdala J, Anasetti C, Jim H. Quality of life after hematopoietic cell transplantation. Blood. 2009;114:7-19.

2. Cantú-Rodriguez OG, Gutiérrez-Aguirre CH, Jaime-Pérez JC, et al. Low incidence and severity of graft-versus-host disease after outpatient allogeneic peripheral blood stem cell transplantation employing a reduced-intensity conditioning. Eur J Haematol. 2011;87;521-30.

3. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González- Llano O, Cantú OE, Hernández NE. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transpl. 2000;25:131-3.

4. Syrjala KL, Langer SL, Abrams JR, Storer BE, Martin PJ. Late effects of hematopoietic stem cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol. 2005;23:6596-606.

5. Cantú-Rodriguez OG, Jaime-Perez JC, Gutiérrez-Aguirre CH, et al. Outpatient allografting using non-myeloablative conditioning: the Mexican experience. Bone Marrow Transplant. 2007;40:119-23.

6. Ruiz-Delgado GJ, Ruiz-Argüelles GJ. A Mexican way to cope with stem cell transplantation. Hematology. 2012;17(Suppl 1):195-7.

7. Pollack SM, O’Connor TP, Hashash J, Tabbara IA. Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review. Am J Clin Oncol. 2009;32:618-28.

8. Ruiz-Argüelles GJ, Gómez-Almaguer D. Editorial: Allografting on outpatient basis can decrease GVHD prevalence, severity. Hem Onc Today. 2012;13:8.

9. Ruiz-Argüelles GJ, Gómez-Almaguer D. Nephrotic syndrome after non-myeloablative stem cell transplantation. Brit J Haematol. 2006;132:801-2.

10. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Ponce- De-León S, Cantú-Rodriguez OG, Jaime-Pérez JC. No cytomegalovirus- related deaths after non-ablative stem cell allografts. Hematolog. 2002;7:95-9.

11. Ruiz-Argüelles GJ, Gómez-Rangel JD, Ponce-de-León S, González- Déctor L, Reyes-Núñez V, Garcés-Eisele J. The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease. Am J Hematol. 2004;75;200-4.

12. Ruiz-Argüelles GJ, Gómez-Almaguer D, Steensma DP. Outdated dogma?: Busulfan, seizure prophylaxis and stem cell allografting. Am J Hematol. 2012;87:941.

13. Zamora-Ortiz G, Velázquez-Sánchez-de-Cima S, Ponce-de-León S, et al. Secondary malignancies after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning and outpatient conduction. Hematology. 2014;19:435-40.

14. Wong R, Giralt SA, Martin T, et al. Reduced intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003;102:3052-9.

15. Bevans MF, Marden S, Leidy NK, et al. Health related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;34:729-38.

16. Díez-Campelo M, Pérez-Simón JA, González-Porras JR, et al. Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic as compare to autologous transplantation: Results of a prospective study. Bone Marrow Transplant. 2004;34:729-38.

17. Leunis A, Ken Redekop W, Uyl-de Groot CA, Lowenberg B. Impaired health-related quality of life in acute myeloid leukemia survivors: A single-center study. Eur J Haematol. 2014;93:198-206.